Analysts Issue Forecasts for ALX Oncology FY2029 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - HC Wainwright issued their FY2029 EPS estimates for ALX Oncology in a research note issued on Friday, January 24th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of $0.63 for the year. HC Wainwright currently has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for ALX Oncology's current full-year earnings is ($2.76) per share.

Several other equities research analysts have also recently weighed in on ALXO. Cantor Fitzgerald reiterated an "overweight" rating on shares of ALX Oncology in a research note on Friday. Jefferies Financial Group lowered shares of ALX Oncology from a "buy" rating to a "hold" rating and dropped their price target for the stock from $12.00 to $2.00 in a research report on Thursday, December 19th. Finally, UBS Group dropped their price target on shares of ALX Oncology from $4.00 to $2.20 and set a "buy" rating for the company in a research report on Monday. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $3.05.

ALX Oncology Stock Performance

Shares of NASDAQ ALXO traded up $0.01 during mid-day trading on Monday, hitting $1.53. The company had a trading volume of 695,634 shares, compared to its average volume of 1,230,024. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The business's 50-day simple moving average is $1.62 and its 200-day simple moving average is $2.33. ALX Oncology has a 12 month low of $1.19 and a 12 month high of $17.83. The firm has a market cap of $80.43 million, a P/E ratio of -0.51 and a beta of 0.98.

Institutional Investors Weigh In On ALX Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALXO. SG Americas Securities LLC boosted its holdings in shares of ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company's stock worth $50,000 after buying an additional 6,888 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of ALX Oncology during the 2nd quarter worth approximately $63,000. GSA Capital Partners LLP bought a new position in ALX Oncology in the 3rd quarter valued at approximately $88,000. Barclays PLC lifted its stake in ALX Oncology by 243.6% in the 3rd quarter. Barclays PLC now owns 59,502 shares of the company's stock valued at $107,000 after purchasing an additional 42,185 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in ALX Oncology by 50.7% in the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company's stock valued at $109,000 after purchasing an additional 6,080 shares during the last quarter. 97.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at ALX Oncology

In related news, Director Rekha Hemrajani acquired 30,000 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The shares were acquired at an average cost of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the acquisition, the director now directly owns 33,000 shares in the company, valued at approximately $51,150. The trade was a 1,000.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 14,443 shares of company stock valued at $23,309 over the last quarter. Corporate insiders own 33.40% of the company's stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.